Generative Artificial Intelligence in Healthcare

Global Generative Artificial Intelligence in Healthcare Market to Reach US$17.0 Billion by 2030

The global market for Generative Artificial Intelligence in Healthcare estimated at US$2.7 Billion in the year 2024, is expected to reach US$17.0 Billion by 2030, growing at a CAGR of 36.0% over the analysis period 2024-2030. Solutions Component, one of the segments analyzed in the report, is expected to record a 34.6% CAGR and reach US$9.7 Billion by the end of the analysis period. Growth in the Services Component segment is estimated at 38.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$704.4 Million While China is Forecast to Grow at 34.3% CAGR

The Generative Artificial Intelligence in Healthcare market in the U.S. is estimated at US$704.4 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.5 Billion by the year 2030 trailing a CAGR of 34.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 32.7% and 31.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 25.3% CAGR.

Global Generative Artificial Intelligence in Healthcare Market – Key Trends & Drivers Summarized

What Are the Transformative Capabilities of Generative AI in Healthcare?

Generative Artificial Intelligence is reshaping healthcare by leveraging its ability to analyze complex datasets and generate predictive models, enabling breakthroughs in diagnostics, treatment, and patient care. By harnessing vast volumes of patient data, medical records, and imaging scans, AI algorithms can deliver precise and timely insights that significantly enhance clinical outcomes. Generative AI`s ability to create new data from existing patterns is particularly valuable in imaging diagnostics, where it identifies diseases such as cancer, heart conditions, and neurological disorders with unparalleled accuracy. Beyond diagnostics, the technology aids in modeling complex biological systems, allowing for the simulation of disease progression and treatment efficacy in silico, reducing the reliance on costly and time-intensive physical experiments. Personalized medicine has emerged as a flagship application of generative AI. By tailoring treatments to individual patients` genetic and lifestyle profiles, AI ensures optimized care with minimal adverse effects. Furthermore, the technology supports medical education and training by simulating rare and complex medical conditions, empowering clinicians to refine their skills in controlled environments. These transformative capabilities of generative AI have established it as a cornerstone of the future of healthcare delivery.

Why Is the Pharmaceutical Sector at the Forefront of Generative AI Adoption?

The pharmaceutical industry is experiencing a paradigm shift as generative AI accelerates drug discovery and development. This technology significantly reduces the traditionally prohibitive time and cost associated with bringing new drugs to market. AI-driven platforms identify promising molecular compounds, simulate their interactions, and predict pharmacological properties, streamlining the preclinical phase. By facilitating virtual drug trials and computational predictions, generative AI minimizes the likelihood of late-stage failures, ensuring higher success rates and faster approval processes. AI`s role in drug repurposing has also proven to be a game-changer. By analyzing existing datasets and exploring new applications for established drugs, pharmaceutical companies can address unmet medical needs more efficiently. Furthermore, generative AI enhances clinical trial management by selecting optimal patient cohorts, ensuring adherence to study protocols, and analyzing real-time data to identify anomalies. These innovations not only improve the speed and accuracy of drug development but also contribute to cost-effectiveness, fostering more robust pipelines for critical therapies.

How Are Healthcare Providers Integrating Generative AI Into Operations?

Hospitals and healthcare providers are embracing generative AI to improve operational efficiency, patient care, and resource utilization. AI-powered systems are revolutionizing administrative workflows, from appointment scheduling and billing to data management and compliance monitoring, allowing healthcare staff to focus on direct patient interactions. Integrating AI with electronic health records (EHRs) ensures that clinicians have access to accurate, up-to-date information, enabling faster and more informed decision-making. Telemedicine has witnessed exponential growth, driven in part by AI-enabled virtual assistants and diagnostic tools. These platforms enhance the quality of remote consultations by offering real-time insights and monitoring capabilities, particularly in underserved and rural areas. Additionally, predictive analytics powered by AI supports hospitals in resource planning by forecasting patient admission trends and optimizing staff deployment. Robotic-assisted surgeries, guided by generative AI, are setting new benchmarks for precision and reducing recovery times. Together, these advancements reflect the growing integration of AI into healthcare ecosystems, ensuring improved outcomes for providers and patients alike.

What Factors Are Driving the Growth of the Generative AI in Healthcare Market?

The growth of the Generative Artificial Intelligence in Healthcare market is driven by several key factors, including the increasing volume of healthcare data, advancements in computational power, and the rising demand for personalized care. The adoption of AI by pharmaceutical companies has been a major catalyst, enabling faster drug discovery and reducing costs. Moreover, the expansion of telehealth services and remote care solutions has fueled demand for AI-powered platforms that facilitate seamless and efficient patient management, particularly in areas with limited healthcare access. Consumer expectations for precision medicine and tailored treatments have pushed healthcare providers to adopt generative AI tools that enhance patient satisfaction and clinical outcomes. Insurers are also turning to AI for fraud detection, risk assessment, and personalized policy creation, broadening the technology`s application across the healthcare landscape. Additionally, governments and private entities are making significant investments in AI research and innovation, with regulatory bodies adapting to ensure ethical deployment and interoperability. These factors collectively underscore the transformative impact of generative AI on the healthcare sector and its role in shaping the future of global health systems.

SCOPE OF STUDY:

The report analyzes the Generative Artificial Intelligence in Healthcare market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Component (Solutions Component, Services Component); Function (Medical Imaging Analysis Function, Virtual Nursing Assistants Function, Robot-Assisted AI Surgery Function, Administrative Process Optimization Function); Application (Clinical Application, System Application); End-Use (Clinical Research End-Use, Medical Centers End-Use, Diagnostic Centers End-Use, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 27 Featured) -

• Amazon Web Services, Inc.
• Deloitte
• ELEKS
• Google Cloud
• IBM Corporation
• Insilico Medicine
• LeewayHertz
• Microsoft Corporation
• Nioyatech LLC
• NVIDIA Corporation

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs CBob geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.